Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Statins and prostate cancer

This article was originally published in The Tan Sheet

Executive Summary

Statin use was associated with a 62% reduction in risk of prostate cancer after adjusting for risk factors, according to a case-control study published in the American Journal of Epidemiology Aug. 15. The risk reduction was especially notable for more aggressive forms of the disease, Jackilen Shannon, Oregon Health & Sciences University, et al., stated. The authors compared statin use in 100 prostate cancer patients with use of the drug in 202 matched controls. Among the cancer patients, 36% had a record of statin use, compared to almost 50% in the control group....

You may also be interested in...



Stockwatch: The Pandemic – Where Generics Failed To Reign

If demand-side pressures on the life science sector were not enough, generic price erosion, debt repayment and extended restructurings are worsening the generic pharmaceutical investment proposition.

QUOTED. 1 March 2021. Xavier Becerra.

California state Attorney General Xavier Becerra promised during two US Senate committee hearings that, if confirmed as Secretary of Health and Human Services, he will let science shape HHS policy.

First Oral Treatment For Spinal Muscular Atrophy Gets EMA Nod

New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel